AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33947856
Drug: PfSPZ vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ vaccine (1.1 × 10^5 aseptic, purified, cryopreserved PfSPZ of the PfNF54 strain) with 10 mg/kg chloroquine base
Trial: 33947856
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) with 10 mg/kg chloroquine base
Trial: 37790581
Drug: PfSPZ vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ vaccine
Trial: 33168081
Drug: Closed incision
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed incision negative pressure wound therapy (ciNPWT) for 7 days
Trial: 34540636
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral medication: cyproterone compound tablets 50 mg BD and diazepam tablets 2 mg TDS for a week)
Trial: 37520237
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (control)
Trial: 35279214
Drug: D‐SOX group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐SOX group (intraperitoneal infusion of docetaxel 30 mg/m2 on d1 and d8, intravenous oxaliplatin 100 mg/m2 on d1, and oral administration of S‐1 on d1‐d14)
Trial: 35279214
Drug: DOS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOS group (intravenous docetaxel 60 mg/m2 on d1, intravenous oxaliplatin 100 mg/m2 on d1, and oral administration of S‐1 on d1‐d14)
Trial: 33761207
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg abrocitinib
Trial: 33761207
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg abrocitinib
Trial: 32457075
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg)
Trial: 32247603
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine (1000 mg/m2 on days 1 and 8 of a 21 day cycle) plus pazopanib (800 mg QD)
Trial: 32247603
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine (1000 mg/m2 on days 1 and 8 of a 21 day cycle) alone
Trial: 32247603
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine plus pazopanib
Trial: 32247603
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine alone
Trial: 32005175
Drug: Continuous intrajejunal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrajejunal Levodopa Infusion (CLI)
Trial: 32080823
Drug: Alirocumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 300 mg
Trial: 33793556
Drug: Rapid immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid immunoglobulin M (IgM)/immunoglobulin G (IgG) test kit
Trial: 32289292
Drug: 4 medications
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 medications
Trial: 36064592
Drug: Guselkumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (all dosing regimens)
Trial: 32776235
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon catheter (DCB) treatment for ISR
Trial: 32776235
Drug: DCB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCB treatment for ISR
Trial: 34657160
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) - Healthy Sleep (HS); 4 sessions over 8 weeks
Trial: 36235860
Drug: Low-absorbable geraniol
RxNorm normalized name: Geraniol
DrugBank: Geraniol (DB14183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-absorbable geraniol food supplement (LAGS) once daily for four weeks
Trial: 35333199
Drug: Cannula injection
RxNorm normalized name: CANNULA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannula injection
Trial: 35609024
Drug: Amoxicillin 250mg
RxNorm normalized name: AMOXICILLIN 250MG CAP
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 250mg capsule with ranitidine
Trial: 35609024
Drug: Amoxicillin 250mg
RxNorm normalized name: AMOXICILLIN 250MG CAP
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 250mg capsule without ranitidine
Trial: 35217280
Drug: Topical ascorbic
RxNorm normalized name: ascorbic acid Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ascorbic acid (30% in 95% DMSO), applied twice daily for 8 weeks
Trial: 35217280
Drug: Topical imiquimod,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod, a standard topical treatment
Trial: 35217280
Drug: Topical ascorbic
RxNorm normalized name: ascorbic acid Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ascorbic acid
Trial: 33879842
Drug: Hydromorphone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone + Dronabinol 2.5 mg
Trial: 33879842
Drug: Hydromorphone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone + Dronabinol 5 mg
Trial: 33879842
Drug: Hydromorphone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone + Dronabinol 10 mg
Trial: 33879842
Drug: Dronabinol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (2.5 mg, 5.0 mg, 10 mg)
Trial: 32027457
Drug: Fostemsavir 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir 1,200 mg b.i.d.
Trial: 32027457
Drug: Fostemsavir 2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir 2,400 mg b.i.d.
Trial: 32027457
Drug: TMR concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMR concentrations up to 7,500 ng/mL
Trial: 32027457
Drug: Fostemsavir 600
RxNorm normalized name: fostemsavir 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir 600 mg b.i.d. (in phase III BRIGHTE study)
Trial: 35012798
Drug: Neoadjuvant dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Trial: 35782290
Drug: Online laughter
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online laughter therapy (10 sessions, 2 days a week for 5 weeks)
Trial: 32567237
Drug: Eye patching
RxNorm normalized name: PATCH,EYE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye patching with a single dose of local steroid and antibiotic for 24 hours
Trial: 32567237
Drug: Plastic shield
RxNorm normalized name: Peroxy Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plastic shield with local steroid and antibiotic drops
Trial: 32621741
Drug: 1 mOPV2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mOPV2 dose
Trial: 32621741
Drug: 2 mOPV2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mOPV2 doses
Trial: 35876018
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase treatment (IVT) followed by endovascular treatment (EVT)
Trial: 35232755
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) alone
Trial: 34167594
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of conjugated estrogens 0.45 mg and bazedoxifene acetate 20 mg (Duavive)
Trial: 35262461
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality technology for intravenous catheterization training
Trial: 35262461
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection arm model (control)
Trial: 32899073
Drug: True acupoints
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True acupoints treatment group (TATG)
Trial: 32899073
Drug: Sham acupoints
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupoints treatment group (SATG)
Trial: 34320413
Drug: ChAdOx1-S (AZD1222)
RxNorm normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ChAdOx1-S (AZD1222) vaccine
Trial: 35727711
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 400 mg
Trial: 35727711
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1600 mg
Trial: 32097092
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 75 mg/m2 every 3 weeks × 4 doses
Trial: 32097092
Drug: Doxorubicin-Cyclophosphamide (AC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-Cyclophosphamide (AC) doxorubicin 60 mg/m2; cyclophosphamide 600 mg/m2 every 2-3 weeks × 4 doses
Trial: 34907536
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent apheresis fresh-frozen plasma (CC-AFFP)
Trial: 35332736
Drug: Oxytocin injection
RxNorm normalized name: Oxytocin Injection
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin injection plus ergometrine injection
Trial: 35332736
Drug: Oxytocin injection
RxNorm normalized name: Oxytocin Injection
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin injection
Trial: 35698580
Drug: Masitinib (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masitinib (6 mg/kg/d)
Trial: 35801005
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg 2 hours before surgery, 40 mg/day after surgery, and 20 mg/day 1 week later
Trial: 35801005
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg every night after admission (Control)
Trial: 34871052
Drug: Best practice
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practice advice with corticosteroid injection
Trial: 34871052
Drug: Best practice
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practice advice without corticosteroid injection
Trial: 32330373
Drug: Verum test
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum test dietary supplement (TDS) containing l-carnitine/acetyl-l-carnitine, l-arginine, glutathione, co-enzyme Q10, zinc, vitamin B9, vitamin B12, selenium, taken 1 time daily for 6 months
Trial: 32330373
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken 1 time daily for 6 months
Trial: 32330373
Drug: Verum test
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum test dietary supplement (TDS)
Trial: 36001306
Drug: Psilocybin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (25 mg/70 kg for first session; 25-40 mg/70 kg for second session)
Trial: 36001306
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg for first session; 50-100 mg for second session)
Trial: 32243943
Drug: Hydrocortisone, vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone, vitamin C, and thiamine combination treatment
Trial: 32481760
Drug: WHS 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHS 300 mg
Trial: 32481760
Drug: WHS 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHS 600 mg
Trial: 32939860
Drug: Brodalumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab (210 mg subcutaneous injections)
Trial: 32216032
Drug: 50 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU/kg Eprex (low-dose)
Trial: 32216032
Drug: 20 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU/kg Eprex (micro-dose)
Trial: 32797324
Drug: L-POCs group
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-POCs group (C-D = I-II)
Trial: 34430440
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy alone (Control group)
Trial: 32820475
Drug: Inotropic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inotropic agents (e.g., dobutamine)
Trial: 33795322
Drug: ICS/LABA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS/LABA therapy for 12 weeks
Trial: 33065820
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Social Rhythm Group Therapy (CBSRT)
Trial: 35790329
Drug: Social Participation-focused
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Participation-focused Virtual Reality (SP-VR) intervention, 6-week program with two sessions weekly.
Trial: 35790329
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (conventional physical therapy services)
Trial: 34791679
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg every 2 weeks for 16 weeks) plus timothy grass (TG) SCIT
Trial: 33439945
Drug: 50 IU/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU/mL heparin solution
Trial: 33439945
Drug: 0.9% isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% isotonic saline solution
Trial: 32887653
Drug: Daily aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily aspirin therapy (100 or 300 mg)
Trial: 39236736
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg infliximab
Trial: 34090870
Drug: 20% Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% Intralipid infusion
Trial: 34703265
Drug: Setipiprant 1000
RxNorm normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant 1000 mg BID
Trial: 35570397
Drug: topical β-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical β-glucan
Trial: 35570397
Drug: 1565-nm NAFL
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1565-nm NAFL combined with topical β-glucan (B + NAFL)
Trial: 35570397
Drug: 1565-nm NAFL
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1565-nm NAFL combined with topical vehicle (NAFL)
Trial: 35570397
Drug: topical vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical vehicle (Veh)
Trial: 32266494
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (CON, n=13)
Trial: 32538776
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus (2 strains, 5 x 10^9 cfu/capsule)
Trial: 35455507
Drug: Massage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage with oil (isio4 10 mL/kg/day)
Trial: 35758895
Drug: Adenosine A2A
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine A2A receptor antagonist
Trial: 34606578
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (2 units, total volume of 550 mL)
Trial: 34507573
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (n=382)
Trial: 34507573
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (Roux-en-Y gastric bypass, n=388; sleeve gastrectomy, n=201)
Trial: 33295083
Drug: Inhaled PDE4i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled PDE4i CHF6001 (tanimilast)
Trial: 36447137
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.375% ropivacaine
Trial: 36447137
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.375% ropivacaine
Trial: 36447137
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 0.375% ropivacaine
Trial: 32092310
Drug: IW-3718 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-3718 1500 mg
Trial: 32092310
Drug: IW-3718 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-3718 500 mg
Trial: 32092310
Drug: IW-3718 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-3718 1000 mg
Trial: 36300974
Drug: DHA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA group (60 mg of DHA per kilogram of body weight per day)
Trial: 33346335
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg/d)
Trial: 33346335
Drug: Efavirenz-based therapy
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz-based therapy
Trial: 32333636
Drug: Financial toxicity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial toxicity sources including travel to and from the hospital and reduced working hours during treatment
Trial: 35936068
Drug: Ketamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (10 μg/kg/min)
Trial: 33333508
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy with VR and MI techniques, 60-min sessions, every alternate day for 12 weeks
Trial: 33333508
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy, 40-min sessions, 20 min of walking and cycling, every alternate day for 12 weeks
Trial: 33228625
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) package offered to half of the smokers interested in receiving it.
Trial: 33228625
Drug: No nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No nicotine patches offered to the other half of smokers.
Trial: 35389359
Drug: Pharmacist-led web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led web-based medication adherence tool with patient-centered communication
Trial: 35763327
Drug: Bionic Pancreas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bionic Pancreas (BP) with insulin aspart or insulin lispro, N=112
Trial: 32271710
Drug: Topical silicone-based
RxNorm normalized name: silicones Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silicone-based scar cream containing selective synthetic recombinant human growth factors, hyaluronic acid, and vitamin C applied twice a day for 1 month.
Trial: 32271710
Drug: Topical silicone-based
RxNorm normalized name: silicones Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silicone-based scar cream (treated group)
Trial: 33706428
Drug: Stepwise pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise pain management (oral acetaminophen 10-15 mg/kg every 4-6 hours for moderate pain, morphine 0.1-0.2 mg/kg every 4 hours for severe pain)
Trial: 34144603
Drug: MTX-PGs levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX-PGs levels >134 nmol/l
Trial: 34556722
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen treatment (35% fraction of inspired oxygen)
Trial: 35940872
Drug: Dextrose gel
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose gel (40% dextrose)
Trial: 34052785
Drug: mHealth technology-centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth technology-centered intervention using a Vaica electronic pill tray and blue-toothed UA-767Plus BT blood pressure device with a dedicated app for data relay.
Trial: 36478707
Drug: Intrathecal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal sufentanil (2 μg) with 10 mg intrathecal bupivacaine